No Detail Found!

Clinical Trial on Entocid Chewable Tablet for Hyperacidity and Gastroesophageal Reflux Disease.

Author(s)
Zubair Ali Department of Medical Affairs and Training, Herbion Pharmaceutical (Pvt.) Limited, Karachi, Pakistan
Muhammad Daniyal Department of Medical Affairs and Training, Herbion Pharmaceutical (Pvt.) Limited, Karachi, Pakistan
Khan Usmanghani Department of Research and Development, Herbion Pharmaceutical (Pvt.) Limited, Karachi, Pakistan
Abstract
Objective: To investigate the therapeutic effects of the herbal medication Entocid chewable Tablet a product of Herbion pharmaceutical on the indications and gastric motility of patients with hyperacidity and gastroesophageal reflux disease (GERD). Methods: Total 50 patients were selected for this study. The patients were selected using a modified Reflux Disease Questionnaire, which is a validated, self-administered scale that is widely used for the assessment of anti-reflux treatment effects. Patients were advised to take study medicine 2 tablets twice daily after meal for 1 week. We take follow up after 1 week. We select the subjects from Sharafi Goth Govt. Hospital Naik Muhammad Dispensary. Results: Entocid Chewable tablets were innocuous and well endured and compact the occurrences of all the evaluated GERD symptoms, with no adverse events requiring withdrawal. Conclusion: Entocid chewable tablets may provide a harmless and active management for decreasing the symptoms of GERD.
Publication Details
Page(s) 2-7
DOI DOI not available
Published Journal: RADS Journal of Pharmacy & Pharmaceutical Sciences, Volume: 5, Issue: 2, Year: 2017

Request the full text from PASTIC

Keywords
gastroesophageal reflux disease
References
LeeSY,LeeKJ,KimSJ,Cho SW, 2009.Prevalence and risk factors for overlaps between gastroesophageal reflux disease, dyspepsia, and irritable bowel syndrome: a population-based study,Digestion 79 196 -201
Locke 3rdGR,TalleyNJ,FettSL,ZinsmeisterAR, 1997.Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota, 112 1448 -56
PetersenH., 1995.The prevalence of gastrooesophageal reflux disease,Scand J Gastroenterol 30 5 -6
DentJ,El-SeragHB,WallanderM,JohanssonS., 2005.Epidemiology of gastro-oesophageal reflux disease: a systematic review,Gut 54 710 -7
McDougallNI,JohnstonBT,KeeF,CollinsJS,McFarlandRJ,LoveAH, .Natural history of reflux oesophagitis: a 10 year follow up of its effect on, -
FarupC,KleinmanL,SloanS,GanoczyD,CheeE,LeeC,RevickiD., 2001.The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life,Arch Intern Med 161 45 -52
YangYX,LewisJD,EpsteinS,MetzDC, .Longterm proton pump inhibitor therapy and risk of hip fracture,JAMA. 2006 Dec 296 2947 -53
AmentPW,DicolaDB,JamesME, 2012.Reducing adverse effects of proton pump inhibitors,Am Fam Physician 86 66 -70
RonkainenJ,AroP,StorskrubbT,LindT,Bolling‐SternevaldE,JunghardO,TalleyNJ, 2006.Gastro‐oesophageal reflux symptoms and health‐related quality of life in the adult general population-the Kalixanda study,Aliment Pharmacol Ther 23 1725 -33
WahlqvistP,ReillyMC,BarkunA, 2006.Systematic review: the impact of gastro‐oesophageal reflux disease on work productivity,Aliment Pharmacol Ther 24 259 -72
LagergrenJ,BergströmR,LindgrenA,NyrénO, 1999.Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma,N Engl J Med 340 825 -31
EdgrenG,AdamiHO,WeiderpassE,NyrénO., 2013.A global assessment of the oesophageal adenocarcinoma epidemic,Gut 62 1406 -14
MasonJ,HunginAP, 2005.gastro‐oesophageal reflux disease-the health economic implications,Aliment Pharmacol Ther 22 20 -31
MittalRK,BalabanDH, 1997.The esophagogastric junction,N Engl J Med 336 924 -32
HershcoviciT,MashimoH,FassR., 2011.The lower esophageal sphincter,Neurogastroenterol Motil 23 819 -30
KessingBF,ConchilloJM,BredenoordAJ,SmoutAJ,MascleeAA., 2011.the clinical relevance of transient lower oesophageal sphincter relaxations in gastro‐oesophageal reflux disease,Aliment Pharmacol Ther 33 650 -61
PenaginiR,BraviI., 2010.The role of delayed gastric emptying and impaired oesophageal body motility,Best Pract Res Clin Gastroenterol 24 831 -45
KandulskiA,MalfertheinerP, 2012.Gastroesophageal reflux disease-from reflux episodes to mucosal inflammation,Nat Rev Gastroenterol Hepatol 9 15 -
PandolfinoJE,El-SeragHB,ZhangQ,ShahN,GhoshSK,KahrilasPJ, 2006.Obesity: a challenge to esophagogastric junction integrity,Gastroenterology 130 639 -49
KahrilasPJ,GuptaRR, 1989.The effect of cigarette smoking on salivation and esophageal acid clearance,J Lab Clin Med 114 431 -8
DennishGW,CastellDO, 1971.The Inhibitory Effect of Smoking on the Lower Esophageal Sphincter,Ann Intern Med 74 834 -
DentJ,El-SeragHB,WallanderM,JohanssonS., 2005.Epidemiology of gastro-oesophageal reflux disease: a systematic review,Gut 54 710 -7
HampelH,AbrahamNS,El-SeragHB, 2005.Metaanalysis: obesity and the risk for gastroesophageal reflux disease and its complications,Ann Intern Med 143 199 -211
NilssonM,JohnsenR,YeW,HveemK,LagergrenJ, 2003.Obesity and estrogen as risk factors for gastroesophageal reflux symptoms,JAMA 290 66 -72
NilssonM,JohnsenR,YeW,HveemK,LagergrenJ, 2004.Lifestyle related risk factors in the aetiology of gastro-oesophageal reflux,Gut 53 1730 -5
CookMB,WildCP,FormanD., 2005.A systematic review and meta-analysis of the sex ratio for Barrett's esophagus, erosive reflux disease, and nonerosive reflux disease,Am J Epidemiol 162 1050 -61
BecherA,DentJ, 2011.Systematic review: ageing and gastro‐oesophageal reflux disease symptoms, oesophageal function and reflux oesophagitis,Aliment Pharmacol Ther 33 442 -54
FlegalKM,CarrollMD,OgdenCL,JohnsonCL, 2002.Prevalence and trends in obesity among US adults,, 288 1723 -7
SinghS,SharmaAN,MuradMH,ButtarNS,ElSeragHB,KatzkaDA,IyerPG, .Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a, -
VakilN,Van ZantenSV,KahrilasP,DentJ,JonesR., 2006.The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus,Am J Gastroenterol 101 1900 -20
ArmstrongD,MarshallJK,ChibaN,EnnsR,FalloneCA,FassR,HollingworthR,HuntRH,KahrilasPJ,MayrandS,MoayyediP.,Canadian Consensus,Can J Gastroenterol Hepatol, 2005.Conference on the management of gastroesophageal reflux disease in adults-update 2004, 19 15 -35
TeferaL,FeinM,RitterMP,BremnerCG,CrookesPF,PetersJH,HagenJA, 1997.Can the combination of symptoms and endoscopy confirm the presence of gastroesophageal reflux disease?,Am Surg 63 933 -6
KahrilasPJ,QuigleyEM., 1996.Clinical esophageal pH recording: a technical review for practice guideline development,Gastroenterology 110 1982 -96
HiranoI,RichterJE, 2007.ACG practice guidelines: esophageal reflux testing,Am J Gastroenterol 102 668 -
ReimerC,SøndergaardB,HilstedL,BytzerP, 2009.Proton-pump inhibitor therapy induces acidrelated symptoms in healthy volunteers after withdrawal of therapy,Gastroenterology 137 80 -7
BavishiC,DupontHL, 2011.Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection,Aliment Pharmacol Ther 34 1269 -81
JohnstoneJ,NerenbergK,LoebM, 2010.Meta‐analysis: proton pump inhibitor use and the risk of community‐acquired pneumonia,Aliment Pharmacol Ther 31 1165 -77
NgamruengphongS,LeontiadisGI,RadhiS,DentinoA,NugentK., 2011.Proton pump inhibitors and risk of fracture: a systematic review and metaanalysis of observational studies,Am J Gastroenterol 106 1209 -
0

Citations

0

Downloads

53

Views